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BACKGROUND 
Antenatal detection of the small for gestational (SGA) fetus has become an important indicator 
of quality of antenatal care in the UK. This has been driven by a desire to reduce stillbirth in 
this at risk group.  
METHODS 
We conducted a postal survey of 187 NHS consultant units within the UK to determine what 
the current practice for the detection and subsequent management of the suspected SGA 
fetus was following the guidance from the Royal College of Obstetricians and Gynaecologists 
(RCOG) in 2013. 
RESULTS 
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The survey was performed in 3 rounds between 2016 and 2017 with a response rate of 65%. 
85% of units assessed risk factors for SGA at booking. 81% of units used a customized 
symphysis fundal height (SFH) chart to screen for SGA with 95% of them using a cut off of 
<10th centile to refer for ultrasound assessment.  
When ultrasound is used to detect SGA, 80% of units used estimated fetal weight (EFW), with 
89% of these using a cut off of <10th centile to diagnose SGA. Umbilical artery (UA) Doppler 
monitoring was undertaken in 97% of management and 94% delivered after 37 weeks. 
Only 24% of units had a dedicated fetal growth clinic, whilst 48% of units were able to offer 
computerised CTG to monitor the SGA fetus. 
CONCLUSIONS 
Overall there is consistency in the screening methods for SGA (customised SFH charts) and 
identification of suspected SGA (SFH <10th centile, EFW <10th centile, UA monitoring and 
induction of labour at term). There was a low uptake of computerized CTG to monitor SGA 
babies and a low number of specialised fetal growth clinics. 
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Introduction 
There has been growing interest in identifying the small for gestational age (SGA) fetus over 
recent years within the UK with new developments in screening for the SGA fetus (1, 2), due 
to greater awareness of the association between a low birth weight and stillbirth. The stillbirth 
rate within the United Kingdom (UK) remains one of the highest in industrialised countries 
(3.87 per 1000 births) (3) but remains uncommon at term (2.0 per 1000 births) (4). To date, 
reducing the incidence of stillbirth remains problematic (5, 6).  
Historically, strategies to prevent stillbirth have focussed on risk factors identifiable in early 
pregnancy (7-14). However, risk factors alone predict less than 20% of all stillbirths (14). In 
39% of stillbirths the cause remains unknown, although 1/3 were likely to be growth restricted 
(14).  
The SGA fetus is at increased risk of stillbirth (7, 8, 15), neonatal adverse outcome (16) with 
potential life-long health risks (17, 18). Therefore, the focus of stillbirth prevention has moved 
to more easily identified group of SGA fetuses in the hope that actively managing these 
pregnancies will reduce the stillbirth rate. 
Unfortunately, our tools to identify the SGA fetus are not as reliable as we would wish. The 
standard approach advocated for all pregnant women in the UK by The National Institute for 
Health and Care Excellence (NICE) relies upon serial measurement of the maternal abdomen 
with a tape measure from 24 weeks to generate the symphysial fundal height (SFH) (19). SGA 
is suspected when SFH measurement is <10th centile or there is static growth over two 
measurements. SFH measurement in isolation has a sensitivity of just 30-40% (1, 20) and no 
randomised controlled studies of the effectiveness of customised SFH charts (21).  
When there is a reduced SFH measurement, referral for ultrasound assessment of fetal growth 
is recommended. If estimated fetal weight (EFW) is <10th centile for gestation a diagnosis of 
a SGA fetus can be made (9, 22, 23). However, antenatal detection of SGA with ultrasound is 
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limited with up to 41% of SGA fetuses remaining undiagnosed and a false positive rate of up 
to 20% (24). The countries that have instigated routine third trimester ultrasound screening for 
SGA, either as a national policy or research, have not demonstrated significantly better 
detection rates (13). 
The Royal College of Obstetricians and Gynaecologists (RCOG) has produced guidance for 
the management of the SGA fetus (23) but acknowledges that the most appropriate regimen 
for surveillance remains unclear (25). The RCOG recommends that the SGA fetus should 
have growth assessed with ultrasound every 2 weeks with additional fetal blood flow (Doppler) 
assessment. Timing of delivery should be based upon deterioration in growth or fetoplacental 
Doppler (<37 weeks) or when the pregnancy exceeds 37+0 weeks even if all other factors are 
normal (23).  
Interestingly, not all national guidelines are as prescriptive (26). Canadian (27) guidance 
suggests close monitoring of fetal condition with ultrasound after 37 weeks but with no defined 
time to deliver. Irish (28), United States of America (26) and New Zealand guidelines  (29) are 
also more conservative,  suggesting that in the presence of normal Doppler studies the SGA 
fetus can be left until 38-39 (Ireland and USA) or 40 weeks (New Zealand).  
Much of the evidence for lack of harm from delaying delivery comes from the DIGITAT study, 
which showed no adverse effects from induction of labour vs delayed delivery (30). This has 
been interpreted by some as evidence in favour of delivering earlier, because of continued 
risk of stillbirth, although this study was underpowered to make a judgement regarding 
perinatal mortality or severe morbidity. Recently, some objections to ‘routine’ early delivery for 
SGA in the absence of any abnormal clinical findings have been raised.  In a recent UK study 
delivery was deferred until 40 weeks if fetal assessment was normal (31).  
This increased intervention and delivery of SGA fetuses at a late preterm or early term 
gestation, whilst well intentioned, is not without potential risks. There is a substantial body of 
evidence that being born <39 weeks has an impact upon a child’s later academic achievement 
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(32-35). SGA fetuses born at term have a cerebral palsy risk 5-7 times greater than normal 
birth weight babies (36, 37), although the possible influence of earlier delivery on this outcome 
remains unknown.  
The desire to reduce stillbirth at the population level is powerful but currently leads to 
substantial and costly interventions for a large number of women which impacts upon women’s 
choice and increases the burden on the health care system. It is worth highlighting that for 
most women individualised risk of stillbirth, even with suspected SGA baby, remains low. New 
innovative strategies are being developed but their impact is uncertain at present (Saving 
Babies Lives Care Bundle) (38).  
We designed this survey to ascertain the current provision of SGA screening and management 
of these pregnancies following the introduction of guidance from the Royal College of 
Obstetricians and Gynaecologists (RCOG) in 2013. 
 
Methods 
A postal survey was conducted in line with our previous surveys (39, 40). The survey was sent 
to all consultant led NHS hospitals in the UK (England, Wales, Scotland, Northern Ireland, 
Channel Islands and Isle of Man). The first round was sent in March 2017, followed by a 
second round in July 2017 to those who had not responded to the initial survey. The survey 
consisted of sixteen questions (5 on screening and 11 on management) to explore the local 
approaches to screening and identification of pregnancies at risk of SGA (Appendix One). 
Further questions were designed to assess the management pathways in place for SGA 
pregnancies and what if any intervention was offered for antenatal and intrapartum care.  
 
Results 
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210 NHS consultant units were identified, 23 were excluded, as they no longer provided 
obstetric services or had merged leaving 187 eligible trusts. 122 units responded to the survey, 
achieving an overall response rate of 65% (122/187). Of the 122 responders, 20 units (16%) 
reported a delivery rate of <2500 births, 61 (50%) a rate of 2500-5000 births and 41 units 
(34%) a rate of >5000 births.  
Clinical Risk Assessment  
103 trusts (85%) offered clinical risk assessment for SGA at booking (Table One). 62 (51%) 
units offered aspirin for pregnancies deemed high risk for SGA. A further 55 (45%) units only 
prescribed aspirin if there was a history of pre-eclampsia and not for SGA risk factors only.  
Screening for SGA 
Nearly all units used customised fetal growth charts (20) to screen pregnancies for SGA (99, 
81%). The rest used either population charts (19, 16%), such as the WHO population chart 
(4, 3%), or newer charts such as the IG21 chart (2). Out of 122 units that use SFH, 107 
(88%) informed us that they used a SFH measurement below a predetermined centile to 
determine the need for assessment with ultrasound.  The remaining 15 (12%) units gave no 
information.  
Only 58/107 (54%) specified the cut-off for referral; 55 (95%) units used a SFH <10th centile 
as a threshold, one used the 5th centile (2%) and two used the 3rd centile (3%), 102 units 
(84%) use a static growth reading over two measurements as an indication for referral.  
98 units (80%) use ultrasound measurement of EFW to define whether a fetus is SGA. The 
commonest EFW centile for diagnosis of SGA was <10th (74/83, 89%), <5th (8/83, 10%) 
and <3rd (1/83, 1%). 46 responders (38%) used an AC, either alone or in combination with 
EFW, to define SGA with the majority using an AC <10th (25/36, 69%), <5th (7/36, 19%) and 
<3rd (4/36, 11%) centiles. Other markers of concern expressed by responders included 
static growth between measurements (72, 59%). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Management of suspected SGA 
29 trusts (24%) offered an assessment in a dedicated fetal growth clinic.  The majority of 
these clinics are led by a consultant obstetrician (27, 93%), of whom half (13, 48%) were 
sub-specialists in maternal and fetal medicine. A further 2 fetal growth clinics were midwife 
led (7%) (Table Two).  
Doppler ultrasound assessment used to monitor SGA included; umbilical artery (UA) (117, 
97%), middle cerebral artery (MCA) (59, 49%), DV (40, 33%), uterine artery (UtA) Doppler 
(27, 22%) and cerebroplacental ratio (CPR). Some units also used biophysical profile (BPP) 
(12, 10%) and liquor volume assessment (9, 7%) (Table Three). 73 responders (60%) did 
not offer additional investigations for SGA cases unless other features of concern were 
present.  
A number of units offer further investigations with maternal blood infection screening (39, 
32%), amniocentesis (genetics) (30, 25%), non-invasive prenatal testing (9, 7%) and 
amniocentesis (infection) (1, <1%). Further referral to a fetal medicine specialist was made 
in 4 units (3%).  
Management of SGA with normal Doppler 
We asked a series of questions about the management of the SGA fetus with normal 
Doppler studies to determine standard practice. The frequency of follow up scans varied 
from weekly (27, 22%), fortnightly (83, 69%), to every 3 weeks (5, 4%) or on a case-by-case 
basis (5, 4%). 
In the presence of SGA with normal Doppler studies, most units did not perform CTG unless 
there were other concerns like decreased fetal movements (79, 67%). Some units did 
routinely offer CTG assessment for SGA pregnancies; either weekly (9, 7%), twice weekly 
(28 24%) or timed with scans (2, 2%). Short-term variability (STV) quantification was 
available on computerised CTG in 63 units (53%), but was only used to inform SGA 
management in 57 (48%) units.  
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Many trusts routinely offered induction of labour delivery following the diagnosis of SGA with 
normal Dopplers, at the following gestational ages; 36-37 weeks (7, 6%), 37-38 weeks (76, 
62%), 38-39 weeks (18, 15%), 39-40 weeks (9, 7%) or >40 weeks (3, 2%) (Table Four). The 
mean induction rates for responding units in 2012 was 24% (IQR 20-29) and in 2016 was 
30% (IQR 25-34). 76 units (70%) reported that in their opinion SGA surveillance had been in 
part responsible for an increase in inductions in their units, whilst 32 trusts (30%) did not feel 
this to be the case.  
Birth weight centile was determined using customised growth charts, such as GROW, in 89 
(75%) trusts, 28 (24%) used traditional population charts, such as the WHO chart, and only 
one trust (1%) used newer population charts, such as IG21. 
 
Discussion  
This is the first survey to assess the real life impact of national guidance on the screening 
and management of SGA pregnancies. Surveys are subject to potential bias, as the 
responses may not reflect the actual practice. We have been, therefore, cautious  not to over 
interpret the results presented but do feel that they give an insight  in  the local 
implementation of national guidance within a state funded health care system which should 
in theory allow for the approach to management to be more consistent. Our data show that, 
there are many aspects of care that are consistently provided, such as SGA screening with 
customised SFH charts with planned delivery at term. However, wide variations in some 
practices remain.  
Half of all units used aspirin to reduce the risk of SGA. With this number rising to >90% if risk 
factors for preeclampsia were also included. However, we did not critique each individual 
unit’s risk factor screening criteria. Since this survey has been performed new evidence has 
emerged on the benefits of a higher dose of 150mg of aspirin taken at night to prevent 
preterm preeclampsia (41). We feel that it is likely that many units will begin to use this dose 
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to prevent SGA as well but we were not able to address this question at the time of 
surveying. 
The majority of units used SFH <10th centile as a screening tool for SGA followed by 
ultrasound assessment using EFW <10th centile to confirm the diagnosis of SGA. The almost 
universal use of UA Doppler once SGA is diagnosed is reassuring. It is also reassuring to 
note the general consistency of a 2 weekly follow up for SGA fetuses with normal Doppler as 
suggested by the RCOG. Our survey highlighted that only 48% of units had regular access 
to computerised CTG with STV to monitor SGA foetuses, despite this being a 
recommendation for surveillance of SGA pregnancies in combination with ultrasound. This 
recommendation is based upon evidence of metabolic acidaemia and early neonatal death 
when the STV is <3.0ms (42).  
Whilst the majority of units conform to the RCOG guidance to deliver from 37 weeks, some 
units are clearly bolder, deferring delivery for SGA with normal Doppler to as late as 41 
weeks. This may be, at first view concerning, however, it is relevant to note that other 
countries’ national guidelines advocate a more nuanced approach to timing of delivery as 
discussed earlier. In addition, at present, there is no definitive evidence that a policy of early 
induction materially affects the stillbirth rate overall. The balance therefore is between 
number of interventions or inductions performed in a population of women with an SGA fetus 
versus the potential to reduce stillbirth. 
There has been a general increase in inductions of labour across the UK since the year prior 
to the GTG on SGA and the year prior to this survey. There are many reasons why the 
induction rate may have increased over this time, including increased awareness of other 
potential risks for stillbirth such as reduced fetal movements and a greater awareness 
amongst clinicians and woman that induction is unlikely to increase the risk of caesarean 
section (43).  
Conclusion 
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It is reassuring to note the commonality in many aspects of SGA screening and management. 
However, there are still many inconsistencies, which raise concerns about the effect of 
national guidance to reduce stillbirth. This may reflect a difficulty to follow guidance when it 
relies heavily upon the use of ultrasound and trained sonographers for which in the UK there 
is a national shortage (44).  
The findings of this survey suggest that there is an urgent need for more high quality studies 
on a standardised approach to the management of the SGA fetus, particularly if the goal is to 
identify the subset of SGA fetuses that is at highest risk of mortality and morbidity.  
It is possible that future advance in management may come from non-ultrasound based 
screening or prognostic tools, such as biomarkers of placental function, the most likely of 
which to be available being sFlt-1 and PlGF, although these remain research tools at present.   
Whilst the response to the survey varied by unit size we feel that it provides a fair reflection of 
the size of maternity units within the UK and as such can be considered representative. We 
would also suggest that the low number of specialist fetal growth clinics may make 
standardisation of care within and between organisations more difficult and could be 
considered a goal for clinical service development.  
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 Table 1. Screening processes for SGA fetuses in UK obstetric clinics.  
  
 
Screening for SGA risk factors at booking N = 121 
Yes  103 (85%) 
No  18 (15%) 
Aspirin for high risk of SGA  N = 121 
Yes 62 (51%) 
Yes but only if history of pre-eclampsia  55 (45%) 
No 4 (3%) 
SFH chart used N = 122 
Customised growth chart (i.e. GROW) 99 (81%) 
Traditional population chart (i.e. WHO chart) 19 (16%) 
Newer population chart (i.e. IG21 chart) 4 (3%) 
SFH criteria for referral for USS (non-exclusive) N = 122 
SFH below a defined centile 107 (88%) 
      <10th  55/58 (95%) 
      <5th 1/58 (2%) 
      <3rd  2/58 (3%) 
Static growth over two measurements  102 (84%) 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Table 2. Diagnostic criteria for ultrasound (non-exclusive) and referral. 
 
  
 
EFW below a predetermined centile: N = 98/122 (80%) 
10th  74/83 (89%) 
5th  8/83 (10%) 
3rd  1/83 (1%) 
AC below a predetermined centile: N = 46/122 (38%) 
10th  25/36 (69%) 
5th  7/36 (19%) 
3rd  4/36 (11%) 
Static Growth over two measurements N = 122 
72 (59%) 
Dedicated fetal growth clinic N = 122 
Yes 29 (24%) 
No 93 (76%) 
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Table 3. Surveillance and investigation of SGA fetuses.  
 
 
 
 
 
  
 
Ultrasound parameters for SGA surveillance (non-
exclusive) 
N = 121 
Umbilical artery (UA) Doppler  117 (97%) 
Middle cerebral artery (MCA) Doppler 59 (49%) 
Ductus venosus (DV) Doppler 40 (33%) 
Uterine artery (UtA) Doppler  27 (22%) 
Cerebro-placental ratio (CPR) 24 (20%) 
Biophysical profile (BPP) 12 (10%) 
Liquor volume (LV) 9 (7%)  
Additional investigations (non-exclusive) N = 121 
None unless other features  73 (60%) 
Screening for infections (maternal blood) 39 (32%) 
Amniocentesis (genetics) 30 (25%) 
Non-invasive prenatal testing (NIPT) 9 (7%) 
Fetal medicine specialist review   4 (3%) 
Screening for infections (amniocentesis) 1 (<1%) 
Frequency of ultrasound assessment on SGA fetuses with 
normal Dopplers  
N = 120 
Weekly  27 (22%) 
Every 2 weeks 83 (69%) 
Every 3 weeks 5 (4%) 
Each case decided on its merits 5 (4%) 
CTG monitoring  N = 118  
Weekly 9 (7%) 
Twice weekly 28 (24%) 
With scans   2 (2%) 
Only if other factors (e.g. reduced fetal movements) 79 (67%) 
Monitoring with short term variability (STV) on cCTG  N = 119  
Available and used routinely 57 (48%) 
Available but not used routinely 6 (5%) 
Not available  56 (47%) AC
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 Table 4. Intrapartum management of the SGA fetus 
 
Gestation for delivery of SGA fetus with normal Dopplers N = 122 
36-37 weeks  7 (6%) 
37-38 weeks 76 (62%) 
38-39 weeks 18 (15%) 
39-40 weeks  9 (7%) 
40+ weeks 3 (2%) 
Induction rates per year 
Mean (IQR) 
 
2012   24% (24, 29) 
2016  30% (25, 34) 
Birthweight assessment  N = 122 
Customised charts e.g. GROW 89 (75%) 
Population centile e.g. WHO 28 (24%) 
New population centile e.g. IG21 1 (1%) 
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